Final assessment report on Midostaurin (Rydapt©)

We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Midostaurin (Rydapt©) with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia” is now available. The final assessment report was published in November 2017. Find the documentation provided by the authoring team here.